
EnginZyme raises €21 million in Series B
In Sweden, cell-free biomanufacturing technology company EnginZyme has raised €21 million (US$22 million). The Series B funding will be used to accelerate commercialization of the company’s platform, which leverages enzymes and the efficiency of the chemical industry. “By replacing traditional fossil-based manufacturing with its patented cell-free technology platform, the company seeks to accelerate the shift […]